Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
MiMedx Group ( (MDXG) ) just unveiled an update.
MiMedx Group reported a record revenue of $114 million for the third quarter of 2025, marking a 35% increase from the previous year, driven by significant growth in its Wound and Surgical franchises. The company is preparing for potential changes in Medicare and Medicaid reimbursement rules, which it believes will stabilize the industry and benefit stakeholders, while maintaining a positive long-term outlook.
The most recent analyst rating on (MDXG) stock is a Hold with a $7.50 price target. To see the full list of analyst forecasts on MiMedx Group stock, see the MDXG Stock Forecast page.
Spark’s Take on MDXG Stock
According to Spark, TipRanks’ AI Analyst, MDXG is a Neutral.
MiMedx Group’s overall stock score is driven by solid financial performance and a positive earnings outlook, despite some profitability pressures and valuation concerns. The technical analysis indicates a lack of strong momentum, and the high P/E ratio suggests limited valuation appeal. The company’s strategic initiatives and growth prospects in the biotechnology sector provide a positive long-term outlook.
To see Spark’s full report on MDXG stock, click here.
More about MiMedx Group
MiMedx Group, Inc. operates in the healthcare sector, focusing on regenerative medicine with a strong emphasis on wound care and surgical products. The company is known for its innovative products such as CELERA™, EMERGE™, AMNIOFIX®, and AMNIOEFFECT®, and is positioned to adapt to changes in Medicare and Medicaid reimbursement rules.
Average Trading Volume: 641,499
Technical Sentiment Signal: Hold
Current Market Cap: $1.02B
For a thorough assessment of MDXG stock, go to TipRanks’ Stock Analysis page.